Compare SKYE & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SKYE | FINW |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 245.2M |
| IPO Year | N/A | 2021 |
| Metric | SKYE | FINW |
|---|---|---|
| Price | $0.74 | $17.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $14.75 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 475.3K | 22.1K |
| Earning Date | 11-10-2025 | 01-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.05 |
| Revenue | N/A | ★ $80,198,000.00 |
| Revenue This Year | N/A | $83.64 |
| Revenue Next Year | N/A | $38.08 |
| P/E Ratio | ★ N/A | $16.79 |
| Revenue Growth | N/A | ★ 14.76 |
| 52 Week Low | $0.70 | $13.49 |
| 52 Week High | $5.75 | $22.49 |
| Indicator | SKYE | FINW |
|---|---|---|
| Relative Strength Index (RSI) | 26.08 | 45.66 |
| Support Level | $0.76 | $17.57 |
| Resistance Level | $0.95 | $18.16 |
| Average True Range (ATR) | 0.10 | 0.53 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 11.35 | 41.99 |
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.